4D Molecular Therapeutics
4D Molecular Therapeutics raises $105M Series D at $800M valuation
Quick Facts
4D Molecular Therapeutics: Series D Funding Round
4D Molecular Therapeutics has successfully raised $105M in Series D funding, reaching a valuation of $800M.
Company Overview
Targeted gene therapy vectors
Funding Details
The Series D round was led by Versant Ventures, with participation from Foresite Capital, Viking Global Investors, Fidelity.
Company Information
- Headquarters: 5858 Horton Street, Emeryville, CA 94608
- Founded: 2013
- Employees: 200+
- Category: Biotech
Investment
4D Molecular Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Versant Ventures: Verified investor in Series D
- Foresite Capital: Verified investor in Series D
- Viking Global Investors: Verified investor in Series D
- Fidelity: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...